AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics

Dow Jones

2025/07/10

By Colin Kellaher

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.

The North Chicago, Ill., biopharmaceutical company said ISB 2001 is currently in Phase 1 studies in patients with relapsed/refractory multiple myeloma.

AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales.

IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 10, 2025 08:26 ET (12:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550640285"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550640285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550640285?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550640285","market":"fut","top_or_hot":-1,"title":"AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a> has struck an immuno-oncology licensing agreement with IGI <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company. \n</p>\n<p>\n  AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. \n</p>\n<p>\n  The North Chicago, Ill., biopharmaceutical company said ISB 2001 is currently in Phase 1 studies in patients with relapsed/refractory multiple myeloma. \n</p>\n<p>\n  AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales. \n</p>\n<p>\n  IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 10, 2025 08:26 ET (12:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-10 20:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ABBV\">AbbVie</a> has struck an immuno-oncology licensing agreement with IGI <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company. \n</p>\n<p>\n  AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. \n</p>\n<p>\n  The North Chicago, Ill., biopharmaceutical company said ISB 2001 is currently in Phase 1 studies in patients with relapsed/refractory multiple myeloma. \n</p>\n<p>\n  AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales. \n</p>\n<p>\n  IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 10, 2025 08:26 ET (12:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999015986.USD","symbol_name":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550640285","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550640285","pubTimestamp":1752150360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales.IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","IGI":"Western Asset Investment Grade D","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","ABBV":"艾伯维公司","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","BK4581":"高盛持仓","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LENZ":"Therapeutics","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"艾伯维(AbbVie)与IGI Therapeutics签订免疫肿瘤许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"LENZ":1,"IGI":1},"content_text":"By Colin Kellaher \n\n\n \n\n\nAbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company. \n\n\n  AbbVie on Thursday said it will pay $700 million up front for an exclusive license to IGI's ISB 2001, a trispecific T-cell engager developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases. \n\n\n  The North Chicago, Ill., biopharmaceutical company said ISB 2001 is currently in Phase 1 studies in patients with relapsed/refractory multiple myeloma. \n\n\n  AbbVie said it will have exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, Japan and Greater China, with IGI eligible to receive up to $1.225 billion in development, regulatory and commercial milestone payments, along with royalties on product sales. \n\n\n  IGI Therapeutics is a unit of New York-based Ichnos Glenmark Innovation, an alliance launched last year by India's Glenmark Pharmaceuticals and its Ichnos Sciences unit. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 08:26 ET (12:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}